IHHT — Intermittent Hypoxia-Hyperoxia Training

Intermittent hypoxia-hyperoxia training (IHHT) cycles a person through alternating low-oxygen and high-oxygen breathing while at rest, an approach derived from altitude-training physiology. It sits in the Gas, Oxidative & Pressure family and serves the atlas as a representative frontier modality: the mechanism is real and unrefuted, the human evidence is early. It is, in other words, the cleanest illustration of the “unproven is not disproven” tier the atlas deliberately keeps visible and separate.

The real substrate — an altitude-training analog

The proposed mechanism is coherent physiology. Alternating hypoxic and hyperoxic breathing cycles are claimed to drive HIF (hypoxia-inducible factor) signalling and mitochondrial biogenesis — the same adaptive pathways that respond to time spent at altitude. This is a genuine, recognised substrate: hypoxia is a real physiological stimulus with known molecular consequences, and the hyperoxic interval is intended to aid recovery between hypoxic doses. The levers are real — degree of hypoxia, cycle timing, session structure — which is what places IHHT among modalities worth studying rather than among incoherent claims.

Claim vs evidence — why grade C

This is the heart of the entry. The mechanism is real, but the clinical evidence is early and mixed, and robust large randomised trials are absent. That combination is exactly what grade C encodes: a genuine mechanism supported so far only by small or inconsistent human data. A 2022 systematic review of intermittent hypoxia–hyperoxia on performance- and health-related outcomes in humans (Behrendt et al., Sports Medicine - Open, 2022) found early, heterogeneous benefits across cardiometabolic and functional endpoints without large confirmatory trials; a controlled study in coronary-artery-disease patients (Glazachev et al., Clinical Cardiology, 2017) similarly reported improved exercise capacity. This is the kind of early, mostly small human evidence that supports the frontier grade without yet establishing the broader rejuvenation claims. The point to hold onto is the asymmetry the atlas insists on: the absence of large positive trials is not evidence of no effect. IHHT has not failed testing; it has not yet been adequately tested at scale. The honest failure mode here is the opposite of the contradicted devices — not an incoherent claim, but a coherent claim being marketed ahead of its evidence.

Why this tier — three independent axes

IHHT sits in the Insufficient-evidence / under-study tier, and the three axes pull apart cleanly. Plausibility is reasonable — real, coherent physiology with a known stimulus. Evidence grade is C — early and mixed, with large RCTs lacking. Tier follows from the combination: a real substrate whose doctrine is unproven but not refuted lands under study, not in either the supported or the contradicted tier. High plausibility does not promote it to Evidence-supported; thin evidence does not demote it to contradicted. The axes are independent, and IHHT lives precisely in the gap.

Regulatory by jurisdiction

Regulatory recognition is correspondingly thin. In the US no FDA device clearance was found and the modality is marketed as wellness; in the EU, CE status varies by device. For Russia, China's NMPA, and Australia's TGA, the source does not specify a status. The reading is straightforward: there is no clearance to anchor a medical claim, and even where a CE mark exists, it would attest to a device meeting requirements for its stated purpose — not to efficacy for rejuvenation. Registration would be market access, never proof.

Lineage — a transnational physiological tradition

IHHT descends from mainstream hypoxia physiology, not from the “frequency” lineage mapped on the lineage page — and that descent is genuinely transnational. The adaptive-hypoxia thread runs from the early hypoxia-tolerance work of Nikolai Sirotinin, through the Bogomoletz Institute of Physiology in Kyiv (where Tetiana Serebrovska's group developed intermittent hypoxia-hyperoxia protocols), to Sechenov University in Moscow (Oleg Glazachev's controlled clinical studies), and onward into Western CE-marked devices and clinics (for example CellGym, TUR, CellOxy, and Aarhus-based programmes). The point is deliberately apolitical: this is one continuous physiological lineage credited across post-Soviet and Western science alike, with no national pejorative attached. What is new is the clinic-and-device packaging around an old, well-travelled idea — real roots, genuine open questions, marketing that has moved faster than the trials.

Keep vs set aside

Keep: the coherent hypoxia-hyperoxia mechanism as a genuine frontier — worth studying for cardiometabolic, rehabilitation, and performance endpoints. Set aside: the “rejuvenation” and anti-aging claims, which are premature — not yet supported by large controlled trials. The discipline here is patience: keep the entry open and under study, and resist both dismissing a real mechanism and overselling it before the evidence arrives.